TSC1/2 mutations as markers of response to everolimus in metastatic renal cell carcinoma: A case study.
Indian J Cancer
; 56(3): 274-275, 2019.
Article
en En
| MEDLINE
| ID: mdl-31389395
We report a case of a 67-year-old man with pazopanib-resistant metastatic renal cell carcinoma (mRCC) who showed an exceptional response to everolimus. Furthermore, this patient had TSC1 and TSC2 mutations. Only a subset of patients with mRCC respond to mTOR inhibitors and emerging evidences indicate that TSC1 and TSC2 mutations could be markers of response to mTOR inhibition. The current case study supports these accruing evidences.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Carcinoma de Células Renales
/
Biomarcadores de Tumor
/
Everolimus
/
Proteína 1 del Complejo de la Esclerosis Tuberosa
/
Proteína 2 del Complejo de la Esclerosis Tuberosa
/
Neoplasias Renales
/
Mutación
Tipo de estudio:
Prognostic_studies
Límite:
Aged
/
Humans
/
Male
Idioma:
En
Año:
2019
Tipo del documento:
Article